PBAC's latest decision on Balsalazide: Recommended (2017). Considered for Treatment of mild-to-moderate active ulcerative colitis, and maintenance of remission, in patients who are intolerant to sulfasalazine.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2017
Submissions
1
2017 → 2017
Eligible population
Patients with mild-to-moderate active ulcerative colitis or in remission who are intolerant to sulfasalazine.
Therapy area
Gastroenterology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
mesalazine
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. This is a minor submission for a pack size increase of an existing listing.